Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candida auris, a multidrug-resistant yeast that causes invasive infections, was first described in 2009 in Japan and has since been reported from several countries. METHODS: To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012-2015 and the type specimen from Japan. Patient information was available for 41 of the isolates. We conducted antifungal susceptibility testing and whole-genome sequencing (WGS). RESULTS: Available clinical information revealed that 41% of patients had diabetes mellitus, 51% had undergone recent surgery, 73% had a central venous catheter, and 41% were receiving systemic antifungal therapy when C. auris was isolated. The median time from admission to infection was 19 days (interquartile range, 9-36 days), 61% of patients had bloodstream infection, and 59% died. Using stringent break points, 93% of isolates were resistant to fluconazole, 35% to amphotericin B, and 7% to echinocandins; 41% were resistant to 2 antifungal classes and 4% were resistant to 3 classes. WGS demonstrated that isolates were grouped into unique clades by geographic region. Clades were separated by thousands of single-nucleotide polymorphisms, but within each clade isolates were clonal. Different mutations in ERG11 were associated with azole resistance in each geographic clade. CONCLUSIONS: C. auris is an emerging healthcare-associated pathogen associated with high mortality. Treatment options are limited, due to antifungal resistance. WGS analysis suggests nearly simultaneous, and recent, independent emergence of different clonal populations on 3 continents. Risk factors and transmission mechanisms need to be elucidated to guide control measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“C. auris, a novel Candida species first identified in 2009, has emerged since 2013 as a cause of nosocomial outbreaks in multiple countries across 5 continents.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [16]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resistance to all three classes of antifungals is reported most commonly in India in South Asia (3%), whereas this is much less common in other regions of the world.122–124”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [122]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Invasive C. auris infections are associated with high mortality rates, with 60% of hospitalizations due to C. auris infections resulting in death (8).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three such mutations, encoding the amino acid substitutions VF125AL (commonly referred to as F126L), Y132F, and K143R, are frequently reported among fluconazole-resistant clinical isolates, and associations between these mutations and specific genetic clades of C. auris have been observed (2).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, up to 96% of C. auris may exhibit resistance to fluconazole, an exceptionally high value compared to 0.5–2% for C. albicans, 4–9% for C. tropicalis, 2–6% for C. parapsilosis, and 11–13% for C. glabrata [16,40,41].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [16]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
Tamura, K., Stecher, G., Peterson, D., Filipski, A., & Kumar, S. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst197 · Cited by 47,205
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · cited 1×
“SNPs were identified using 2 independent pipelines, as described elsewhere (see also the legend to Supplemental Figure 1) [15, 19].”
MethodEpidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“auris because we did not have a comparison group of patients with other Candida infections from the same institutions [31].”
BackgroundResultNonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data
Chin, C.-S., Alexander, D. H., Marks, P., Klammer, A. A., Drake, J., Heiner, C., Clum, A., Copeland, A., Huddleston, J., Eichler, E. E., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2474 · Cited by 4,029 · cited 1×
“The reference genome was generated by de novo assembly of PacBio reads from isolate B8441, as described elsewhere [18], and used as a reference for single-nucleotide polymorphism (SNP) calling.”
MethodSatoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381 · cited 8×
“To understand the global emergence and epidemiology of C. auris, we obtained isolates from 54 patients with C. auris infection from Pakistan, India, South Africa, and Venezuela during 2012–2015 and the type specimen from Japan.”
BackgroundInfluentialEvolution of pathogenicity and sexual reproduction in eight Candida genomes
Butler, G., Rasmussen, M. D., Lin, M. F., Santos, M. A. S., Sakthikumar, S., Munro, C. A., Rheinbay, E., Grabherr, M., Forche, A., Reedy, J. L., et al. (2009) · Nature · doi:10.1038/nature08064 · Cited by 1,065 · cited 1×
“5 Mb, similar to that of other Candida species [25].”
BackgroundSelf-citationKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“It phenotypically resembles Candida haemulonii and requires use of molecular methods for identification [9, 10].”
MethodSelf-citationFirst Three Reported Cases of Nosocomial Fungemia Caused by Candida auris
Lee, W. G., Shin, J. H., Uh, Y., Kang, M. G., Kim, S. H., Park, K. H., & Jang, H.-C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00319-11 · Cited by 523 · cited 2×
“auris [3], establishing that this new species was capable of causing invasive infections.”
BackgroundPerea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454 · cited 1×
“auris may become widely established within certain regions, as evidenced by the fact that it now accounts for nearly 5% of candidemia in Indian intensive care units [5].”
Background
Cited by
Items 101–200 of 1,007
Chen, J., Tian, S., Han, X., Chu, Y., Wang, Q., Zhou, B., & Shang, H. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05543-0 · Cited by 159
Candida auris Genetics and Emergence
Chowdhary, A., Jain, K., & Chauhan, N. (2023) · Annual Review of Microbiology · doi:10.1146/annurev-micro-032521-015858 · Cited by 158
Self-citationCombined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris
Kean, R., & Ramage, G. (2019) · mSphere · doi:10.1128/msphere.00458-19 · Cited by 152
“Y132F, K143R, and F126L, and appear to be clade related (4).”
Emerging fungal pathogen Candida auris evades neutrophil attack
Johnson, C. J., Davis, J. M., Huttenlocher, A., Kernien, J. F., & Nett, J. E. (2018) · mBio · doi:10.1128/mbio.01403-18 · Cited by 157
The world’s ten most feared fungi
Hyde, K. D., Al‐Hatmi, A. M. S., Andersen, B., Boekhout, T., Buzina, W., Dawson, T. L., Eastwood, D. C., Jones, E. B. G., de Hoog, S., Kang, Y., et al. (2018) · Fungal Diversity · doi:10.1007/s13225-018-0413-9 · Cited by 167
Self-citationFrom the Pipeline to the Bedside: Advances and Challenges in Clinical Metagenomics
Chiang, A. D., & Dekker, J. P. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz151 · Cited by 176
“investigations [1, 2, 16, 17], pathogen typing or identification”
Current perspective on emergence, diagnosis and drug resistance in Candida auris
Sarma, S., & Upadhyay, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s116229 · Cited by 146
Abdolrasouli, A., Armstrong‐James, D., Ryan, L., & Schelenz, S. (2017) · Mycoses · doi:10.1111/myc.12699 · Cited by 150
The antifungal arsenal: alternative drugs and future targets
Wiederhold, N. P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.09.002 · Cited by 149
First Candida auris Outbreak during a COVID-19 Pandemic in a Tertiary-Care Center in Lebanon
Allaw, F., Kara Zahreddine, N., Ibrahim, A., Tannous, J., Taleb, H., Bizri, A. R., Dbaibo, G., & Kanj, S. S. (2021) · Pathogens · doi:10.3390/pathogens10020157 · Cited by 141
“Its occurrence can range from colonization to invasive disease and candidemia with a high mortality rate reaching 68% [9].”
BackgroundCandida auris : An emerging multidrug-resistant pathogen
Sears, D., & Schwartz, B. S. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.08.017 · Cited by 146
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
Bruno, M., Kersten, S., Bain, J. M., Jaeger, M., Rosati, D., Kruppa, M. D., Lowman, D. W., Rice, P. J., Graves, B., Ma, Z., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0780-3 · Cited by 145
Self-citationBriano, F., Magnasco, L., Sepulcri, C., Dettori, S., Dentone, C., Mikulska, M., Ball, L., Vena, A., Robba, C., Patroniti, N., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00625-9 · Cited by 136
“auris is its unfavorable profile of resistance to antifungal agents, with[ 90% of strains being resistant to fluconazole, 35% to amphotericin B, and over 40% expressing combined resistance to two or more classes of antifungals [6].”
BackgroundHuang, X., Hurabielle, C., Drummond, R. A., Bouladoux, N., Desai, J. V., Sim, C. K., Belkaid, Y., Lionakis, M. S., & Segre, J. A. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.12.002 · Cited by 144
“Clinical reports have suggested that broad-spectrum antibiotic or azole antifungal preexposure and diabetes may be associated with C. auris colonization and/or infection (Khan et al., 2018; Lockhart et al., 2017; Parra-Giraldo et al., 2018).”
BackgroundInfluentialFungal Lanosterol 14α-demethylase: A target for next-generation antifungal design
Monk, B. C., Sagatova, A. A., Hosseini, P., Ruma, Y. N., Wilson, R. K., & Keniya, M. V. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.02.008 · Cited by 164
Liu, F., Hu, Z.-D., Zhao, X.-M., Zhao, W.-N., Feng, Z.-X., Yurkov, A., Alwasel, S., Boekhout, T., Bensch, K., Hui, F.-L., et al. (2024) · Persoonia - Molecular Phylogeny and Evolution of Fungi · doi:10.3767/persoonia.2024.52.02 · Cited by 143
Synthetic macromolecules as therapeutics that overcome resistance in cancer and microbial infection
Tan, J., Tay, J., Hedrick, J. L., & Yang, Y. Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120078 · Cited by 149
Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris
Rybak, J. M., Doorley, L. A., Nishimoto, A. T., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-19 · Cited by 141
“auris (fluconazole MIC, 1 to 8 mg/liter) harboring the Y132F or K143R mutation have been reported, suggesting the presence of additional mechanisms of triazole resistance yet to be identified (1, 9).”
BackgroundIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139
“Fluconazole was the least active drug tested with both an MIC50 and MIC90 of 64 g/ml, an observation consistent with widespread resistance that has been reported elsewhere (2).”
BackgroundInfluentialAntifungal Resistance: a Concerning Trend for the Present and Future
Hendrickson, J. A., Hu, C., Aitken, S. L., & Beyda, N. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0702-9 · Cited by 139
Kwon, Y. J., Shin, J. H., Byun, S. A., Choi, M. J., Won, E. J., Lee, D., Lee, S. Y., Chun, S., Lee, J. H., Choi, H. J., et al. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01624-18 · Cited by 135
“In addition, the ERG11 gene encoding the azole target was sequenced to study the mechanism of resistance to azoles (2, 6), and multilocus sequencing typing (MLST) and pulsed-field gel electrophoresis (PFGE) were performed to investigate the genetic relationships among the C.”
BackgroundMethodResultInfluentialExpandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
Candida auris: Epidemiology, risk factors, virulence, resistance, and therapeutic options
de Cássia Orlandi Sardi, J., Silva, D. R., Soares Mendes-Giannini, M. J., & Rosalen, P. L. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.09.014 · Cited by 134
Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016–20171
van Schalkwyk, E., Mpembe, R. S., Thomas, J., Shuping, L., Ismail, H., Lowman, W., Karstaedt, A. S., Chibabhai, V., Wadula, J., Avenant, T., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190040 · Cited by 137
“auris isolates from South Africa are resistant to fluconazole (2) (T.”
BackgroundSelf-citationKim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.02529-18 · Cited by 136
“auris transcripts were annotated based on a published putative transcript list (6, 16, 18, 34).”
BackgroundSelf-citationIdentification of Drug Resistant Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01918 · Cited by 124
“A high vigilance still needs to be in place when identification process results in C. haemulonii, C. duobushaemulonii, C. famata, C. glabrata from (not updated) VITEK 2 (bioMérieux), C. famata, C. sake, Rhodotorula glutinis, Saccharomyces cerevisiae from API 20C AUX (bioMérieux), C. haemulonii, C. parapsilosis, C. cat…”
InfluentialGnat, S., Łagowski, D., Nowakiewicz, A., & Dyląg, M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15032 · Cited by 155
Chakrabarti, A., & Sood, P. (2021) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001318 · Cited by 133
Emergence of Candida auris: An International Call to Arms
Clancy, C. J., & Nguyen, M. H. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw696 · Cited by 129
Sabino, R., Veríssimo, C., Pereira, Á. A., & Antunes, F. (2020) · Microorganisms · doi:10.3390/microorganisms8020181 · Cited by 133
“auris isolates from the different regions (East Asia, South Asia, Africa, and South America) [11].”
BackgroundInfluentialConserved Role for Biofilm Matrix Polysaccharides in Candida auris Drug Resistance
Dominguez, E. G., Zarnowski, R., Choy, H. L., Zhao, M., Sanchez, H., Nett, J. E., & Andes, D. R. (2019) · mSphere · doi:10.1128/mspheredirect.00680-18 · Cited by 132
“mortality rates near 60% in some case series (2).”
BackgroundCandida auris Infection and Biofilm Formation: Going Beyond the Surface
Horton, M. V., & Nett, J. E. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00143-7 · Cited by 132
Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins
Borman, A. M., Szekely, A., & Johnson, E. M. (2017) · Medical Mycology · doi:10.1093/mmy/myw147 · Cited by 132
Beardsley, J., Halliday, C. L., Chen, S. C.-A., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 124
Climate change brings the specter of new infectious diseases
Casadevall, A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135003 · Cited by 124
Lionakis, M. S., & Chowdhary, A. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2402635 · Cited by 130
Self-citationIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
Self-citationThe changing epidemiology of fungal infections
Lass‐Flörl, C., & Steixner, S. J. M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101215 · Cited by 151
Membrane-Interacting Antifungal Peptides
Struyfs, C., Cammue, B. P. A., & Thevissen, K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.649875 · Cited by 138
Fungal impacts on Earth’s ecosystems
Case, N. T., Gurr, S. J., Fisher, M. C., Blehert, D. S., Boone, C. M., Casadevall, A., Chowdhary, A., Cuomo, C. A., Currie, C. R., Denning, D. W., et al. (2025) · Nature · doi:10.1038/s41586-024-08419-4 · Cited by 139
“Although direct proof is lacking, one hypothesis is that the dual use of azoles on crops and in the clinic has accelerated the rise of highly azole-resistant C. auris 126 , in which multiple mutations contribute to resistance in most isolates 127,128 .”
Self-citationFakhim, H., Vaezi, A., Dannaoui, E., Chowdhary, A., Nasiry, D., Faeli, L., Meis, J. F., & Badali, H. (2018) · Mycoses · doi:10.1111/myc.12754 · Cited by 122
Self-citationClade-specific chromosomal rearrangements and loss of subtelomeric adhesins in Candida auris
Muñoz, J. F., Welsh, R. M., Shea, T., Batra, D., Gade, L., Howard, D., Rowe, L. A., Meis, J. F., Litvintseva, A. P., & Cuomo, C. A. (2021) · Genetics · doi:10.1093/genetics/iyab029 · Cited by 125
“In addition, we closely examined rearrangements associated with copy number variation in ERG11, one of the mechanisms contributing to azole-resistance in C. auris (Mu~noz et al. 2018; Bhattacharya et al. 2019) predominantly observed in Clade III isolates (Chow et al. 2020).”
BackgroundResultInfluentialSelf-citationSzekely, A., Borman, A. M., & Johnson, E. M. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.02055-18 · Cited by 125
Candida auris: What Have We Learned About Its Mechanisms of Pathogenicity?
Rossato, L., & Colombo, A. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03081 · Cited by 121
“…for the first time an MDR yeast pathogen with a high capacity to cause clusters of invasive infections in medical centers around the world (Kim et al., 2009; Lee et al., 2011; Chowdhary et al., 2013, 2014; Calvo et al., 2016; Prakash et al., 2016; Lockhart et al., 2017; Morales-Lopez et al., 2017).”
BackgroundSelf-citationvan Rhijn, N., & Bromley, M. (2021) · Journal of Fungi · doi:10.3390/jof7050367 · Cited by 132
Rybak, J. M., Barker, K. S., Muñoz, J. F., Parker, J. E., Ahmad, S., Mokaddas, E., Abdullah, A., Elhagracy, R. S., Kelly, S. L., Cuomo, C. A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.024 · Cited by 120
Self-citationChindamporn, A., Chakrabarti, A., Li, R., Sun, P.-L., Tan, B.-H., Chua, M., Wahyuningsih, R., Patel, A., Liu, Z., Chen, Y.-C., et al. (2018) · Medical Mycology · doi:10.1093/mmy/myx066 · Cited by 117
The Postbiotic Activity of Lactobacillus paracasei 28.4 Against Candida auris
Rossoni, R. D., de Barros, P. P., Mendonça, I. D. C., Medina, R. P., Silva, D. H. S., Fuchs, B. B., Junqueira, J. C., & Mylonakis, E. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00397 · Cited by 102
“The emergence of C. auris is concerning because this yeast has or may develop resistance to different antifungal agents (Lockhart et al., 2017; Chaabane et al., 2019), making infections difficult to treat.”
BackgroundCastanheira, M., Deshpande, L. M., Davis, A. P., Rhomberg, P. R., & Pfaller, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00906-17 · Cited by 114
“Reports of breakthrough infections (22), increasing prevalence of uncommon 254 species refractory to clinically available antifungal agents (23, 24), and emerging resistance mechanisms 255”
BackgroundSelf-citationCandida auris Outbreaks: Current Status and Future Perspectives
Gaetano, S. D., Midiri, A., Mancuso, G., Avola, M. G., & Biondo, C. (2024) · Microorganisms · doi:10.3390/microorganisms12050927 · Cited by 125
“Whole genome sequencing (WGS) and single nucleotide polymorphism analysis, combined with epidemiological observations, have shown that genetically unrelated clonal populations of C. auris emerged independently and simultaneously in different geographical areas [63].”
BackgroundLara, H. H., Ixtepan-Turrent, L., Jose Yacaman, M., & Lopez-Ribot, J. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b20708 · Cited by 116
Hog1 regulates stress tolerance and virulence in the emerging fungal pathogen Candida auris
Day, A. M., McNiff, M. M., da Silva Dantas, A., Gow, N. A. R., & Quinn, J. (2018) · mSphere · doi:10.1128/msphere.00506-18 · Cited by 116
“auris to be separated into 4 distinct geographic clades, namely, the South Asian, East Asian, South African, and South American clades, which are separated by tens of thousands of single polynucleotide polymorphism differences (5).”
BackgroundInfluentialQuindós, G., Marcos‐Arias, C., San-Millán, R., Mateo, E., & Eraso, E. (2018) · International Microbiology · doi:10.1007/s10123-018-0014-1 · Cited by 131
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings
Caceres, D. H., Forsberg, K., Welsh, R. M., Sexton, D. J., Lockhart, S. R., Jackson, B. R., & Chiller, T. (2019) · Journal of Fungi · doi:10.3390/jof5040111 · Cited by 109
“Antifungal resistance of C. auris isolates varies across the phylogenetic clades, but multidrug-resistance is common, especially among isolates of the South Asia clade [13] .”
BackgroundMethodSelf-citationGenomics for Emerging Pathogen Identification and Monitoring: Prospects and Obstacles
Vashisht, V., Vashisht, A., Mondal, A. K., Farmaha, J. K., Alptekin, A., Singh, H., Ahluwalia, P. K., Srinivas, A., & Kolhe, R. B. (2023) · BioMedInformatics · doi:10.3390/biomedinformatics3040069 · Cited by 134
Rybak, J. M., Cuomo, C. A., & David Rogers, P. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102208 · Cited by 113
Self-citationAn Overview on Candida auris in Healthcare Settings
Cristina, M. L., Spagnolo, A. M., Sartini, M., Carbone, A., Oliva, M., Schinca, E., Boni, S., & Pontali, E. (2023) · Journal of Fungi · doi:10.3390/jof9090913 · Cited by 124
“Four distinct clades (South American clade, African clade, South Asian clade and East Asian clade) have been identified from separate geographic origins, suggesting a recent and nearly simultaneous emergence of different clonal populations [12].”
BackgroundYeasticidal activity of chemical disinfectants and antiseptics against Candida auris
Moore, G., Schelenz, S., Borman, A. M., Johnson, E. M., & Brown, C. S. (2017) · Journal of Hospital Infection · doi:10.1016/j.jhin.2017.08.019 · Cited by 122
Yadav, A., Singh, A., Wang, Y., Haren, M. H. V., Singh, A., de Groot, T., Meis, J. F., Xu, J., & Chowdhary, A. (2021) · Journal of Fungi · doi:10.3390/jof7020081 · Cited by 111
“Data Availability Statement: All the nine isolates were submitted to GenBank under accession number SAMN17149510-18.”
BackgroundInfluentialSelf-citationTreatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“auris, and breakthrough infection on echinocandins has been noted [16,90,91].”
BackgroundActivity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.021 · Cited by 110
Self-citationCandidiasis and Other Emerging Yeasts
Sharma, M., & Chakrabarti, A. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00455-3 · Cited by 123
“The different clades of C. auris exhibit variable rates of antifungal resistance: Clade I—high drug resistance (fluconazole, 97%; voriconazole, 54%; amphotericin B, 30%; 49% MDR); Clade II—low drug resistance (11–14% to fluconazole); Clade III—high drug resistance to fluconazole and voriconazole, but susceptible to am…”
BackgroundKhan, Z., Ahmad, S., Al-Sweih, N., Joseph, L., Alfouzan, W., & Asadzadeh, M. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195743 · Cited by 109
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Self-citationAdhesins of Yeasts: Protein Structure and Interactions
Willaert, R. G. (2018) · Journal of Fungi · doi:10.3390/jof4040119 · Cited by 98
“conserved sequence repeats, but lack glycosylphosphatidylinositol (GPI) anchor attachment signals; the C‐terminal location of their ligand‐binding domains suggests an alternative form of cell wall attachment [44,46].”
Di Pilato, V., Codda, G., Ball, L., Giacobbe, D. R., Willison, E., Mikulska, M., Magnasco, L., Crea, F., Vena, A., Pelosi, P., et al. (2021) · Journal of Fungi · doi:10.3390/jof7020140 · Cited by 107
“html, accessed 10 January 2021) or previously adopted by other studies were used [15].”
BackgroundMethodCandida auris otomycosis in Iran and review of recent literature
Abastabar, M., Haghani, I., Ahangarkani, F., Rezai, M. S., Taghizadeh Armaki, M., Roodgari, S., Kiakojuri, K., Al‐Hatmi, A. M. S., Meis, J. F., & Badali, H. (2019) · Mycoses · doi:10.1111/myc.12886 · Cited by 107
Self-citationForgács, L., Borman, A. M., Prépost, E., Tóth, Z., Kardos, G., Kovács, R., Szekely, A., Nagy, F., Kovacs, I., & Majoros, L. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1771218 · Cited by 107
“Retrospective identification by DNA sequencing revealed the earliest known strain of C. auris was a bloodstream isolate from 1996 in a paediatric surgery patient in Korea, and the next earliest was found in 2008 in Pakistan [3].”
BackgroundInfluentialResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
Berkow, E. L., Angulo, D., & Lockhart, S. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00435-17 · Cited by 103
“auris can exhibit in vitro resistance to multiple antifungal agents – creating a 24 challenge for clinicians directing treatment (1-3).”
BackgroundSelf-citationCandida Biofilms: An Update on Developmental Mechanisms and Therapeutic Challenges
de Barros, P. P., Rossoni, R. D., de Souza, C. M., Scorzoni, L., Fenley, J. D. C., & Junqueira, J. C. (2020) · Mycopathologia · doi:10.1007/s11046-020-00445-w · Cited by 121
Recent Trends in the Epidemiology of Fungal Infections
Seagle, E. E., Williams, S., & Chiller, T. M. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.001 · Cited by 114
Self-citationCandida auris: a global fungal public health threat
Meis, J. F. G. M., & Chowdhary, A. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30609-1 · Cited by 110
Self-citationLyman, M., Forsberg, K., Reuben, J., Dang, T., Free, R., Seagle, E. E., Sexton, D. J., Soda, E., Jones, H., Hawkins, D., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7029a2 · Cited by 104
Self-citationIn Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris
Fakhim, H., Chowdhary, A., Prakash, A., Vaezi, A., Dannaoui, E., Meis, J. F., & Badali, H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-17 · Cited by 102
Self-citationBhattacharya, S., Holowka, T., Orner, E. P., & Fries, B. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-41513-6 · Cited by 101
Shastri, P. S., Shankarnarayan, S. A., Oberoi, J., Rudramurthy, S. M., Wattal, C., & Chakrabarti, A. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.01.004 · Cited by 103
Emerging Antifungal Resistance in Fungal Pathogens
Hui, S. T., Gifford, H., & Rhodes, J. L. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00219-8 · Cited by 118
“The main cause of fluconazole resistance and therefore treatment failure is centred on amino acid substitutions within the ERG11 gene, which are also restricted by genetic clade: Y132F and K143R in Clade I, only Y132F in Clades IV and V and F126L in Clade III [33, 35].”
BackgroundInfluentialKim, H. Y., Nguyen, T. A., Kidd, S. E., Chambers, J., Alastruey‐Izquierdo, A., Shin, J.-H., Dao, A., Forastiero, A., Wahyuningsih, R., Chakrabarti, A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae042 · Cited by 123
“The overall mortality rate s in patients with C. auris infection 8 , 18, 21, 22, 25, 46, 47, 51 or candidaemia 18 , 21 , 25, 46, 47, 51 ranged from 29% to 62% (Table 2 ).”
BackgroundWhat has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Bravo Ruiz, G., Ross, Z. K., Gow, N. A. R., & Lorenz, A. (2020) · mSphere · doi:10.1128/msphere.00151-20 · Cited by 101
“auris clinical isolates (Table S2) covering the four major clades (43) by treatment with HU (Figs.”
BackgroundMethodNobrega de Almeida, J., Brandão, I. B., Francisco, E. C., de Almeida, S. L. R., de Oliveira Dias, P., Pereira, F. M., Santos Ferreira, F., de Andrade, T. S., de Miranda Costa, M. M., de Souza Jordão, R. T., et al. (2021) · Mycoses · doi:10.1111/myc.13320 · Cited by 100
Self-citationThe Candida auris Alert: Facts and Perspectives
Lamoth, F., & Kontoyiannis, D. P. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix597 · Cited by 95
Nine Things Genomics Can Tell Us About Candida auris
Chybowska, A. D., Childers, D. S., & Farrer, R. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00351 · Cited by 96
“GENOMIC EPIDEMIOLOGY OF C. auris Since 2009, five genetically diverse clades have been discovered from India and Pakistan (South Asian; Clade I), Japan (East Asian; Clade II), South Africa (African; Clade III), Venezuela (South American; Clade IV) (Lockhart et al., 2017b) and most recently in 2019, Iran (Clade V) (Cho…”
BackgroundInfluentialMulti-omics Signature of Candida auris , an Emerging and Multidrug-Resistant Pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S. P., Clair, G. C., Bredeweg, E. L., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · mSystems · doi:10.1128/msystems.00257-19 · Cited by 99
“auris has been classified into four distinct clades according to their biogeography (31).”
BackgroundCandida auris : multi-omics signature of an emerging and multidrug-resistant pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S., Clair, G., Bredeweg, E., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · doi:10.1101/528232 · Cited by 99
de Jong, A. W., & Hagen, F. (2019) · Mycopathologia · doi:10.1007/s11046-019-00351-w · Cited by 95
Candida auris in South Africa, 2012–2016
Govender, N. P., Magobo, R. E., Mpembe, R., Mhlanga, M., Matlapeng, P., Corcoran, C., Govind, C., Lowman, W., Senekal, M., & Thomas, J. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2411.18-0368 · Cited by 96
Self-citationAmbaraghassi, G., Dufresne, P. J., Dufresne, S. F., Vallières, É., Muñoz, J. F., Cuomo, C. A., Berkow, E. L., Lockhart, S. R., & Luong, M.-L. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00884-19 · Cited by 90
“auris is now recognized as a major global health concern (11).”
BackgroundInfluentialSelf-citationPharmacodynamic Optimization for Treatment of Invasive Candida auris Infection
Lepak, A. J., Zhao, M., Berkow, E. L., Lockhart, S. R., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-17 · Cited by 89
“Candida auris is an emerging multidrug-resistant threat to human health across the globe (1, 2).”
BackgroundSelf-citationCandida auris: An emerging drug resistant yeast – A mini-review
Bidaud, A. L., Chowdhary, A., & Dannaoui, E. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.06.007 · Cited by 94
“Among 54 patients with C. auris infection from Pakistan, India, South Africa and Venezuela, 93% of isolates were resistant to fluconazole, 54% to voriconazole, 35% to amphotericin B, 7% to echinocandins and 6% to flucytosine.”
BackgroundInfluentialSelf-citationBarber, C. A., Crank, K. C., Papp, K., Innes, G. K., Schmitz, B. W., Chavez, J., Rossi, A., & Gerrity, D. W. (2023) · Environmental Science & Technology · doi:10.1021/acs.est.2c07763 · Cited by 98
Welsh, R. M., Sexton, D. J., Forsberg, K., Vallabhaneni, S., & Litvintseva, A. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.00007-19 · Cited by 90
“Each clade is strongly associated with distinct geographic regions and differs from other clades by tens of thousands of single-nucleotide polymorphisms (SNPs), while the genetic diversity within a clade is extremely low (10).”
BackgroundSelf-citationAraúz, A. B., Caceres, D. H., Santiago, E., Armstrong, P., Arosemena, S., Ramos, C., Espinosa‐Bode, A., Borace, J., Hayer, L., Cedeño, I., et al. (2018) · Mycoses · doi:10.1111/myc.12709 · Cited by 92
Self-citationHospital-Associated Multicenter Outbreak of Emerging Fungus Candida auris, Colombia, 2016
Armstrong, P. A., Rivera, S. M., Escandon, P., Caceres, D. H., Chow, N., Stuckey, M. J., Díaz, J., Gomez, A., Vélez, N., Espinosa-Bode, A., et al. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2507.180491 · Cited by 92
“auris isolates collected from 4 world regions, nearly all (93%) were resistant to fluconazole, and 41% were resistant to >2 classes of antifungal drugs (13).”
BackgroundMethodInfluentialSelf-citationAn update on the routine application of MALDI-TOF MS in clinical microbiology
Welker, M., van Belkum, A., Girard, V., Charrier, J., & Pincus, D. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1645603 · Cited by 100
Ghannoum, M., Arendrup, M. C., Chaturvedi, V. P., Lockhart, S. R., McCormick, T. S., Chaturvedi, S., Berkow, E. L., Juneja, D., Tarai, B., Azie, N., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9090539 · Cited by 90
“auris were also identified from clinical isolates [15,16,18].”
BackgroundSelf-citationAntifungal Resistance in Candida auris: Molecular Determinants
Frías-De-León, M. G., Hernández-Castro, R., Vite-Garín, T., Arenas, R., Bonifaz, A., Castañón-Olivares, L., Acosta-Altamirano, G., & Martínez-Herrera, E. (2020) · Antibiotics · doi:10.3390/antibiotics9090568 · Cited by 93
Metadata
- Authors
- Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., Berkow, E. L., Castanheira, M., Magobo, R. E., Jabeen, K., Asghar, R. J., Meis, J. F., Jackson, B., Chiller, T., & Litvintseva, A. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Aga Khan University (PK)
- University of Delhi (IN)
- National Health Laboratory Service (ZA)
- Universidade Federal de São Paulo (BR)
- Universidad del Zulia (VE)
- Broad Institute (US)
- JMI Laboratories (US)
- Radboud University Nijmegen (NL)
- ORCID
- Lockhart, Shawn R.
- Vallabhaneni, Snigdha
- Farooqi, Joveria
- Chowdhary, Anuradha
- Govender, Nelesh P.
- Colombo, Arnaldo Lopes
- Cuomo, Christina A.
- Desjardins, Christopher A.
- Berkow, Elizabeth L.
- Castanheira, Mariana
- Magobo, Rindidzani E.
- Jabeen, Kauser
- Asghar, Rana J.
- Meis, Jacques F.
- Jackson, Brendan
- Chiller, Tom
- Litvintseva, Anastasia P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-20
- Volume
- 64
- Issue
- 2
- Pages
- 134-140
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC5215215
- OpenAlex
- W2536287248
- Semantic Scholar
- c8d8e54651d8fb7a7ece68270cd2630d1cd0df39
- Cited by
- 1,662
- References
- 32
- Citations by year
- 2026: 196 · 2025: 194 · 2024: 203 · 2023: 186 · 2022: 160 · 2021: 178 · 2020: 187 · 2019: 152 · 2018: 116 · 2017: 81 · 2016: 5
- FWCI
- 108.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- public-domain
- Locations
- Clinical Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI110818)
- United States Agency for International Development (4-338/PAK-US/HEC/2010/932)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, multidrug resistance, antifungal resistance, clonal populations, ERG11 mutations, azole resistance, fluconazole resistance, bloodstream infection, invasive candidiasis, nosocomial infections, risk factors, transmission, whole genome sequencing, antifungal susceptibility
- MeSH terms
- Whole Genome Sequencing, Adolescent, Adult, Aged, Antifungal Agents, Candida, Candidiasis, Child, Child, Preschool, Cytochrome P-450 Enzyme System, Female, Humans, Infant, Infant, Newborn, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Phylogeny, RNA, Ribosomal, 28S, Global Health, Genome, Fungal, Drug Resistance, Multiple, Polymorphism, Single Nucleotide, DNA, Ribosomal Spacer, Drug Resistance, Fungal, Young Adult, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.